Designation
-
EU grants SB1518 orphan drug designation
The European Commission (EC) has granted orphan drug designation to S*BIO SB1518, its potent and orally active JAK2 inhibitor for the treatment of primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and postessential thrombocyt…
Designation | 04 November 2010
-
AMT Receives Orphan Drug Designation for DMD Treatment
Amsterdam Molecular Therapeutics (AMT) has announced that the European Medicines Agency (EMEA) has granted Orphan Drug Designation to the former’s gene therapy product AMT-080 for the treatment of Duchenne Muscular Dystrophy (DMD). Orphan Drug …
Designation | 22 October 2009
-
Axentis Pharma Receives Orphan Drug Designation
Axentis Pharma has announced that the Office of Orphan Products Development of the US Food and Drug Administration (FDA) has granted the orphan drug designation to the former's lead product candidate, Fluidosomes-tobramycin. This drug is a liposo…
Designation | 08 May 2009
